Inovalon (INOV) reported earnings on Wed 30 Oct 19 (a/h)

• Update: Acquired by Nordic Capital and Insight Partners for $7.3 Billion. (Aug 19, 2021) 

** charts before earnings **

 

** charts after earnings **

Inovalon beats by $0.03, reports revs in-line; guides FY20 EPS above consensus, revs above consensus

Reports Q3 (Sep) earnings of $0.15 per share, $0.03 better than the S&P Capital IQ Consensus of $0.12; revenues rose 14.2% year/year to $166.5 mln vs the $164.92 mln S&P Capital IQ Consensus.

Annual Contract Value (ACV) for new sales totaled $44.1 mln.

Reports Adjusted EBITDA of $56.3 mln, up 7% yr/yr, resulting in Adjusted EBITDA margin of 33.8%.

Co issues upside guidance for FY20, sees EPS of $0.57-$0.61 vs. $0.56 S&P Capital IQ Consensus; sees FY20 revs of $698-$718 mln vs. $697.73 mln S&P Capital IQ Consensus.

Inovalon (INOV) reported earnings on Tue 8 May 2018 (a/h)

• BOWIE, Md. (AP) _ Inovalon Holdings Inc. (INOV) on Tuesday reported a first-quarter loss of $16.3 million, after reporting a profit in the same period a year earlier.

** charts before earnings **

 

** charts after earnings **

 

Inovalon misses by $0.10, misses on revs; guides FY18 EPS below consensus, reaffirms FY18 revs guidance 

• Reports Q1 (Mar) loss of $0.04 per share, excluding non-recurring items, $0.10 worse than the Capital IQ Consensus of $0.06; revenues fell 14.4% year/year to $92.76 mln vs the $107.76 mln Capital IQ Consensus.
  • Cost of revenue for the first quarter of 2018 was $33.5 million, or 36.1% of revenue, compared with $38.3 million, or 35.3% of revenue for the first quarter of 2017.
• Co issues guidance for FY18, sees EPS of $0.32-0.38, excluding non-recurring items, vs. $0.39 Capital IQ Consensus Estimate; sees FY18 revs of $568-593 mln vs. $576.37 mln Capital IQ Consensus Estimate.
  • previous EPS guidance was $0.36-0.42

Long trade : INOV +20% (9/17)

INOV — is it a sell?

• 13 Feb:  Is INOV a sell?

• 2 months later:  NO

Inovalon (INOV) cuts 2016 revenue and earnings guidance

• Lowers FY16 guidance due to inability to enter into expected collaboration agreement as a result of unforeseen circumstances impacting counter-party.

** charts after guidance **

  

On Monday, the Maryland-based technology company said it reduced its guidance as it was unable to enter a collaboration agreement for an application in development, as a result of "unforeseen circumstances impacting the counter-party."

"While this is certainly not the situation we expected or desired, it does demonstrate the level of market opportunity for our platform capabilities, the significance of value that can be driven by those capabilities, and the size and scale at which Inovalon is being called upon to partner and deliver them," CEO Keith Dunleavy said in a statement.
Inovalon now expects full-year earnings per share between 32 cents and 33 cents and revenues in the range of $426 million to $428 million. The company previously forecast earnings per share of 39 cents to 46 cents and revenue between $470 million to $490 million.

Analysts previously projected Inovalon to report full-year earnings of 44 cents per share on revenue of $472.8 million, according to Thomson Reuters consensus estimates.

The stock has fallen more than 44 percent year to date.

** chart one week before guidance **

• Buy point about 6 weeks after guidance drop:

Inovalon (INOV) reported earnings on Wed 2 Nov 2016 (a/h)

** charts after earnings **

  

BOWIE, Md. (AP) _ Inovalon Holdings Inc. (INOV) on Wednesday reported third-quarter earnings of $7.8 million.

On a per-share basis, the Bowie, Maryland-based company said it had profit of 5 cents.

The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 6 cents per share.

The health technology company posted revenue of $105 million in the period, beating Street forecasts. Four analysts surveyed by Zacks expected $100.7 million.

Inovalon Holdings expects full-year earnings in the range of 39 cents to 46 cents per share, with revenue in the range of $470 million to $490 million.

Inovalon Holdings shares have decreased 21 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $13.50, a drop of 42 percent in the last 12 months.

Inovalon (INOV) reported earnings Wed 3 Aug 2016 (a/h)

** charts after earnings **

  

• Q2 revenue miss, and FY16 EPS and revenue guidance below consensus.

Second Quarter 2016 Highlights

• Second quarter revenue of $123.8 million
• Second quarter net income of $16.3 million, resulting in diluted net income of $0.11 per share
• Second quarter Non-GAAP net income of $20.6 million, resulting in Non-GAAP diluted net income of $0.14 per share
• Second quarter Adjusted EBITDA of $40.8 million
• MORE2 Registry® dataset medical event count expanded to more than 11.7 billion
• Accelerating transition to pure cloud-based platform and adjusting 2016 financial guidance

Inovalon (INOV) reported earnings on Wed 4 Nov 2015 (a/h)

** charts 2 days after earnings **

  

• 10 days later: